Our approach supports the role of AKT1 and MDM2 protein signatures as drivers of EMT in melanoma cancer and suggests that MDM2 plus AKT1 inhibitors could be a promising combination for a novel anti-metastatic regimen in high E2F1-expressing melanoma patients. Here, AKT1 is linked to melanoma.